Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG099
MIFTS: 67

Lung Disease

Categories: Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lung Disease

About this section

MalaCards integrated aliases for Lung Disease:

Name: Lung Disease 12 15
Lung Diseases 55 43 44 73
Disorder of Lung 29

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:850
ICD10 33 J98.4 J60-J70
MeSH 44 D008171
NCIt 50 C3198
UMLS 73 C0024115
Sources

Summaries for Lung Disease

About this section
MedlinePlus : 43 When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary : Lung Disease, also known as lung diseases, is related to interstitial lung disease and desquamative interstitial pneumonia, and has symptoms including apnea, coughing and dyspnea. An important gene associated with Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are Metabolism of proteins and IL-17 Family Signaling Pathways. The drugs Lansoprazole and Zinc have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are homeostasis/metabolism and mortality/aging

Disease Ontology : 12 A lower respiratory tract disease in which the function of the lungs is adversely affected by narrowing or blockage of the airways resulting in poor air flow, a loss of elasticity in the lungs that produces a decrease in the total volume of air that the lungs are able to hold, and clotting, scarring, or inflammation of the blood vessels that affect the ability of the lungs to take up oxygen and to release carbon dioxide.

Sources

Related Diseases for Lung Disease

About this section

Diseases related to Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 472)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 33.6 ABCA3 CXCL8 IFIH1 IL1B ITGA3 MUC5B
2 desquamative interstitial pneumonia 33.3 MUC5B SFTPC
3 pneumoconiosis 33.3 CXCL8 IL1B MUC5B TNF
4 alpha-1-antitrypsin deficiency 33.2 CXCL8 ELANE SERPINA1
5 extrinsic allergic alveolitis 33.1 CXCL8 IL1B SFTPD
6 surfactant dysfunction 33.1 ABCA3 SFTPA1 SFTPB SFTPC
7 bagassosis 33.1 CXCL8 IL1B
8 bronchopulmonary dysplasia 33.0 CXCL8 ELANE SFTPB
9 aspergillosis 33.0 CFTR ELANE SFTPA2 SFTPD
10 pulmonary disease, chronic obstructive 33.0 CFTR CXCL8 ELANE SERPINA1 SFTPB SFTPD
11 pulmonary alveolar proteinosis 33.0 SFTPB SFTPC SFTPD
12 allergic bronchopulmonary aspergillosis 33.0 CFTR SFTPA2 SFTPD
13 silicosis 33.0 CXCL8 IL1B SFTPD TNF
14 cystic fibrosis 32.9 CFTR CXCL8 ELANE SERPINA1 SFTPD
15 bronchiolitis 32.8 CXCL8 MUC5B TNF
16 pulmonary fibrosis 32.5 IL1B MUC5B SFTPA1 SFTPA2 SFTPC SFTPD
17 respiratory distress syndrome in premature infants 32.3 ABCA3 SFTPA1 SFTPB SFTPC
18 respiratory failure 32.2 CXCL8 ELANE SERPINA1 SFTPB SFTPC SFTPD
19 idiopathic interstitial pneumonia 32.1 CXCL8 ELANE MUC5B SFTPA1 SFTPA2 SFTPC
20 pneumonia 31.9 CXCL8 ELANE IL1B MUC5B SFTPB SFTPC
21 pulmonary fibrosis, idiopathic 31.4 ABCA3 CXCL8 ELANE IL1B MUC5B SFTPA1
22 mycobacterium abscessus 31.4 CFTR CXCL8 SERPINA1 TNF
23 bronchiectasis 31.3 CFTR CXCL8 ELANE SERPINA1
24 haemophilus influenzae 31.0 CXCL8 IL1B TNF
25 bronchitis 30.9 CFTR CXCL8 ELANE SERPINA1 TNF
26 chorioamnionitis 30.8 CXCL8 ELANE IL1B TNF
27 neonatal respiratory failure 30.7 ABCA3 SFTPB SFTPC
28 sarcoidosis 1 30.7 IL1B SFTPD TNF
29 pulmonary emphysema 30.6 ELANE SERPINA1 SFTPD
30 adult respiratory distress syndrome 30.4 CXCL8 ELANE SFTPB SFTPC TNF
31 contact dermatitis 30.4 CXCL8 IL1B TNF
32 pulmonary edema 30.3 CFTR CXCL8 IL1B TNF
33 periodontitis 30.1 CXCL8 IL1B TNF
34 vasculitis 30.1 ELANE SERPINA1 TNF
35 acute respiratory distress syndrome 29.9 CXCL8 ELANE IL1B SFTPB SFTPC SFTPD
36 autoimmune pancreatitis 29.8 CFTR TNF
37 rheumatoid lung disease 12.3
38 nontuberculous mycobacterial lung disease 12.2
39 interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital 12.2
40 children's interstitial lung disease 12.2
41 lung disease, immunodeficiency, and chromosome breakage syndrome 12.1
42 drug or radiation exposure-related interstitial lung disease 11.9
43 respiratory bronchiolitis-interstitial lung disease syndrome 11.9
44 surfactant metabolism dysfunction, pulmonary, 2 11.7
45 anthracosis 11.5
46 chronic beryllium disease 11.5
47 interstitial pneumonitis, desquamative, familial 11.5
48 farmer's lung 11.4
49 autoimmune interstitial lung, joint, and kidney disease 11.3
50 byssinosis 11.2

Graphical network of the top 20 diseases related to Lung Disease:



Diseases related to Lung Disease
Sources

Symptoms & Phenotypes for Lung Disease

About this section

UMLS symptoms related to Lung Disease:


apnea, coughing, dyspnea, hemoptysis, snoring, labored breathing

MGI Mouse Phenotypes related to Lung Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ABCA3 CFTR ELANE IFIH1 IL1B ITGA3
2 mortality/aging MP:0010768 10.03 ABCA3 CFTR ELANE IFIH1 IL1B ITGA3
3 immune system MP:0005387 10 CFTR ELANE IFIH1 IL1B ITGA3 MUC5B
4 neoplasm MP:0002006 9.56 SFTPC TERT TNF TSC1 TSC2 ELANE
5 respiratory system MP:0005388 9.36 CFTR ITGA3 MUC5B SFTPA1 SFTPB SFTPC
Sources

Drugs & Therapeutics for Lung Disease

About this section

Drugs for Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1246)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 103577-45-3 3883
2
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 23994
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 137-58-6 3676
4
Spironolactone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1952-01-7, 52-01-7 5833
5
Tazobactam Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 89786-04-9 123630
6
Etomidate Approved Phase 4,Not Applicable 33125-97-2 36339 667484
7
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
8
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2 9004-61-9 53477741
9
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 216503-57-0
10
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-31-9 3440
11
Sulfamethoxazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 723-46-6 5329
12
Amikacin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 37517-28-5 37768
13
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 242138-07-4
14
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
15
Selenium Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 7782-49-2
16
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
17
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
18
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 79902-63-9 54454
19
Metformin Approved Phase 4,Phase 2,Early Phase 1 657-24-9 14219 4091
20
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
21
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 54-85-3 3767
22
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-23-7 5754
23
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
24
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28523-86-6 5206
25
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
26
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 114-07-8 12560
27
Mechlorethamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-75-2 4033
28
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
29
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772 46507594
30
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 564-25-0 54671203
31
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
32
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5458213 5381226
33
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
34
Telithromycin Approved Phase 4,Phase 3,Phase 2 191114-48-4 5462516 0
35
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 69-65-8 453 6251
36
Ganciclovir Approved, Investigational Phase 4,Phase 2,Phase 1 82410-32-0 3454
37
Nifedipine Approved Phase 4,Phase 3 21829-25-4 4485
38
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83905-01-5 55185 447043
39
Fenoterol Approved, Investigational Phase 4,Phase 3,Not Applicable 13392-18-2 3343
40
Clarithromycin Approved Phase 4,Phase 3,Phase 2 81103-11-9 84029
41
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
42
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 10118-90-8 5281021
43
Ephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 299-42-3 9294
44
Penicillin G Approved, Vet_approved Phase 4,Phase 3 61-33-6 5904
45
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
46
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51333-22-3 63006 5281004
47
Trimethoprim Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 738-70-5 5578
48
Cefepime Approved, Investigational Phase 4,Phase 3,Not Applicable 88040-23-7 5479537
49
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 90-82-4 7028
50
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Prevention of Chronic Lung Disease (CLD) in Preterm Infants Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
3 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
4 Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD) Unknown status NCT00132860 Phase 4 azithromycin
5 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
6 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
7 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
8 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
9 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
10 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
11 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
12 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01116063 Phase 4 Inhaled iloprost
13 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
14 The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits Unknown status NCT01107613 Phase 4
15 Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00288548 Phase 4 Metoprolol
16 Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
17 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4 Advair;Flovent
18 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
19 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
20 Pulmonary Gas Exchange Response to Indacaterol in COPD Unknown status NCT02547558 Phase 4 Indacaterol
21 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
22 Simvastatin in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
23 Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD Unknown status NCT00860938 Phase 4 Budesonide
24 Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD Unknown status NCT02773797 Phase 4 IN-DEX 1.0 mcg/kg, intranasal saline;IN-DEX 1.5 mcg/kg, intranasal saline;Placebo - Saline
25 Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
26 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
27 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
28 The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
29 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
30 Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Unknown status NCT00731770 Phase 4 fluticasone/salmeterol 250/50;placebo
31 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
32 Secondhand Smoke Respiratory Health Study Unknown status NCT02797275 Phase 4 Albuterol;Placebo
33 AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Unknown status NCT01460108 Phase 4
34 Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation Unknown status NCT01513655 Phase 4
35 An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
36 Strategy to Improve Adherence of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
37 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
38 Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
39 Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients Unknown status NCT01037387 Phase 4 Control
40 Preterm Infant Inhaled Albuterol Dosing Unknown status NCT02447250 Phase 4 Varied albuterol dose response
41 Bronchiolitis All-study, SE-Norway Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
42 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
43 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
44 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4 Tadalafil;Vardenafil
45 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
46 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
47 Transfusion Strategies in Weaning Patients Unknown status NCT01256645 Phase 4
48 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
49 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
50 Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo

Search NIH Clinical Center for Lung Disease

Cochrane evidence based reviews: lung diseases

Sources

Genetic Tests for Lung Disease

About this section

Genetic tests related to Lung Disease:

# Genetic test Affiliating Genes
1 Disorder of Lung 29
Sources

Anatomical Context for Lung Disease

About this section

MalaCards organs/tissues related to Lung Disease:

41
Lung, Testes, Heart, Bone, Neutrophil, Endothelial, T Cells
Sources

Publications for Lung Disease

About this section

Articles related to Lung Disease:

(show top 50) (show all 2649)
# Title Authors Year
1
Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. ( 29936475 )
2018
2
Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease. ( 29353024 )
2018
3
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease. ( 29914454 )
2018
4
Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. ( 28379478 )
2018
5
Exertional Oxygen Requirements During Exercise Training in Advanced Interstitial Lung Disease. ( 29952810 )
2018
6
Renewed Promise of Non-ionizing Radiation Imaging for Chronic Lung Disease in Preterm Infants. ( 29944841 )
2018
7
Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function. ( 29966637 )
2018
8
Galectin-3 Interacts with the CHI3L1 Axis and Contributes to Hermansky-Pudlak Syndrome Lung Disease. ( 29427412 )
2018
9
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. ( 29382380 )
2018
10
Screening for pulmonary hypertension in interstitial lung disease: Many reasons to ECHO! ( 29415370 )
2018
11
Right extrapleural completion pneumonectomy for fibrocavitary nontuberculous mycobacterial lung disease. ( 29445484 )
2018
12
Safety of performing transbronchial lung cryobiopsy on hospitalized patients with interstitial lung disease. ( 29957284 )
2018
13
The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study. ( 29977547 )
2018
14
Unclassifiable Interstitial Lung Disease: Time to Shrink the Black Box. ( 29957036 )
2018
15
Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement. ( 29745875 )
2018
16
Lemierre's syndrome: cavitary lung disease caused by uncommon bacteria. ( 29669776 )
2018
17
Re-administration of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Who Recovered from Chemotherapy-induced Interstitial Lung Disease. ( 29936470 )
2018
18
Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. ( 29376545 )
2018
19
Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy? ( 29382307 )
2018
20
Granulomatous-lymphocytic interstitial lung disease at the emergency department: Think about it! ( 29970784 )
2018
21
Smoking-Related Stigma Expressed by Physiotherapists toward Individuals with Lung Disease. ( 29434420 )
2018
22
Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report. ( 29338781 )
2018
23
The Four Corners Sign: A Specific Imaging Feature in Differentiating Systemic Sclerosis-related Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. ( 29346191 )
2018
24
The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease. ( 29319036 )
2018
25
Autoreactive T cells to citrullinated HSP90 are associated with interstitial lung disease in rheumatoid arthritis. ( 29968330 )
2018
26
Risk factors for primary SjAPgren syndrome-associated interstitial lung disease. ( 29850114 )
2018
27
Tackling injustices of occupational lung disease acquired in South African mines: recent developments and ongoing challenges. ( 29954399 )
2018
28
Diagnostic value of CYFRA 21-1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease. ( 29970696 )
2018
29
KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease. ( 29961690 )
2018
30
Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood. ( 29580292 )
2018
31
Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. ( 29446698 )
2018
32
Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes. ( 29607151 )
2018
33
Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary SjAPgren syndrome patients: A case-control study. ( 29901591 )
2018
34
SjAPgren Syndrome Complicated with Cystic Lung Disease and Pulmonary Amyloidosis. ( 29808154 )
2018
35
Bronchial wash culture is less valuable in patients suspected to have nontuberculous mycobacteria lung disease for bilateral bronchiectasis with nodules. ( 29900897 )
2018
36
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. ( 29422324 )
2018
37
The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. ( 29325580 )
2018
38
Measures that matter: Health-related quality of life in children with interstitial lung disease. ( 29943900 )
2018
39
Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses. ( 29301535 )
2018
40
Mica pneumoconiosis: a neglected occupational lung disease. ( 29759917 )
2018
41
Physiological predictors of Hypoxic Challenge Testing (HCT) outcomes in Interstitial Lung Disease (ILD). ( 29414453 )
2018
42
Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. ( 29430176 )
2018
43
International management platform for children's interstitial lung disease (chILD-EU). ( 29056600 )
2018
44
Five-year follow-up of participants diagnosed with chronic airflow obstruction in a South African Burden of Obstructive Lung Disease (BOLD) survey. ( 29429447 )
2018
45
Hepatopulmonary Syndrome and Diffuse Interstitial Lung Disease: An Unusual Combination. ( 29588084 )
2018
46
Should hut lung be called domestically acquired particulate lung disease or domestically acquired pneumoconiosis? ( 29487788 )
2018
47
Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review. ( 29417209 )
2018
48
Nontuberculous mycobacterial lung disease in a patient with COPD and bronchiectasis, with radiological signs of lung tumor. ( 29490418 )
2018
49
Prognosis of Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies: Look in the Middle. ( 29920503 )
2018
50
Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. ( 29348183 )
2018